Sanofi: CHMP Recommends Approval Of Dupixent For Children With Severe Asthma With Type2 Inflammation
31/1 07:28
(RTTNews) - The European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion, recommending to extend the approval of Dupixent or dupilumab in the European Union to include add-on maintenance treatment for children aged 6 to 11...